The Cooper Companies Competitive Intelligence & Landscape

The Cooper Companies (coopercos.com) is a global, consumer-centric medical device company dedicated to helping people experience life's beautiful moments by supporting how they want to live at every stage of life [coopercos.com]. Headquartered in San Ramon, California, The Cooper Companies operates with a mission to fulfill current healthcare needs while focusing on future opportunities through innovation and strategic investment [coopercos.com, coopercos.com/contact/].

The company is comprised of two primary business units: CooperVision and CooperSurgical [coopercos.com, investor.coopercos.com].

CooperVision is a recognized leader in the contact lens industry, dedicated to improving vision, while CooperSurgical provides best-in-class devices for women's health and surgical procedures [coopercos.com/our-company/, investor.coopercos.com]. These units collectively elevate standards of care through their offerings [coopercos.com/our-company/].

The Cooper Companies operates on a global scale, boasting over 15,000 employees located in 130 countries across Europe, Asia, Africa, and the Americas [coopercos.com/our-company/, coopercos.com/careers/]. The company emphasizes a purpose-driven culture, valuing health, wellness, and a dynamic team environment [coopercos.com/careers/]. They are committed to sound corporate governance and serving as a prudent fiduciary for shareholders [investor.coopercos.com/corporate-governance].

The Cooper Companies (coopercos.com) operates as a global medical device company through two primary business segments: CooperVision and CooperSurgical [coopercos.com]. While the company's official website outlines its innovative products and services in vision care, women's health, and fertility, it does not explicitly detail specific pricing plans, tiers, or recent pricing changes for its medical devices and solutions. The focus is on highlighting the advancements and benefits of their offerings rather than direct consumer pricing.

CooperSurgical, a key segment of The Cooper Companies, offers a diversified portfolio in fertility and women's health care [investor.coopercos.com/static-files/d141ee7e-35b1-47f5-8011-7d94ba240df4]. This includes products for medical use, such as newborn stem cell preservation, which aims to provide expecting parents with more possibilities through state-of-the-art lab services [coopercos.com/coopersurgical/]. These offerings are generally provided as "practice-enhancing tools" to hospitals, surgical centers, medical offices, and fertility clinics [coopercos.com/practice-enhancing-tools/].

For its CooperVision segment, The Cooper Companies is actively working to deliver consistent market share gains, particularly with the global rollout of its MyDay premium daily silicone hydrogel lens portfolio and through various global private label contracts [investor.coopercos.com/static-files/9a2148ca-9e35-4849-a842-bf3c29b22792]. While specific pricing is not publicly disclosed, the company acknowledges the use of practices such as volume discounts, contractual pricing allowances, and rebates in its financial reporting [investor.coopercos.com/static-files/4991c171-a634-4552-85a1-f86d00d7ad9c]. These indicate a B2B sales model where pricing is likely negotiated based on volume and contractual agreements, rather than fixed, publicly advertised pricing tiers.

There is no mention of free versus paid features or recent pricing changes available on the public-facing areas of coopercos.com or its investor relations site, as the company primarily targets healthcare providers rather than individual consumers for direct sales of its medical devices. The company's strategic priorities include accelerating product rollouts and securing new contracts, suggesting that competitive and negotiated pricing structures are in place for its institutional and private label partners [investor.coopercos.com/news-releases/news-release-details/coopercompanies-announces-fourth-quarter-and-full-year-2025].

The Cooper Companies is a global, consumer-centric medical device company with over 15,000 employees spread across 130 countries, headquartered in San Ramon, CA [coopercos.com/our-company/]. The company actively recruits to support its diverse operations, emphasizing a commitment to helping people experience life's beautiful moments [coopercos.com]. Their careers page highlights available openings and encourages interested individuals to explore opportunities to join their team [coopercos.com/careers/].

The Cooper Companies demonstrates a commitment to nurturing new talent through its Global Internship Program. This paid program offers university and college students from various fields the chance to engage in high-impact initiatives, expanding their skills beyond academic settings [coopercos.com/careers/]. Interns like Bella Arredondo, a 2024 Internal Communications Specialist, have praised the company's culture for fostering innovation and collaboration [coopercos.com/global-internship-program/]. This indicates a strategic investment in developing future employees and maintaining a pipeline of skilled professionals.

While specific layoff information is not available, The Cooper Companies focuses on creating a strong internal culture, aiming to be a "global employer of choice." They strive for safe, supportive, and fair workplaces that foster a sense of belonging and allow employees to reach their full potential [coopercos.com/connection-belonging/]. This emphasis on Connection & Belonging suggests a strategy geared towards employee retention and growth within the company.

The company's proactive hiring, including its internship program, aligns with its mission to elevate standards of care through innovation and strategic investment [coopercos.com]. Recent recognition as a Best Workplace for Innovators in September 2024 further supports this, highlighting a company culture that drives innovation for its customers and patients [investor.coopercos.com/news-releases/news-release-details/coopercompanies-recognized-best-workplace-innovators]. This continuous investment in talent signals a growth-oriented strategy with a focus on medical device advancements.

The Cooper Companies (coopercos.com) demonstrates a strong financial performance as a leading global medical device company, trading on Nasdaq under the ticker COO [investor.coopercos.com]. The company reported significant revenue figures for both its fiscal fourth quarter and full year ended October 31, 2025. Fourth-quarter 2025 revenue reached $1,065.2 million, marking a 5% increase (or 3% organically), while the fiscal year 2025 revenue totaled $4.1 billion, representing a 5% increase (or 4% organically) [investor.coopercos.com/news-releases/news-release-details/coopercompanies-announces-fourth-quarter-and-full-year-2025].

Continuing its growth trajectory, The Cooper Companies also announced its fiscal first quarter 2026 results. For the quarter ended January 31, 2026, revenue stood at $1.024 billion, an increase of 6% (or 3% organically) compared to the prior year's first quarter. GAAP diluted earnings per share (EPS) for this period were $0.66, reflecting a substantial 27% increase [investor.coopercos.com/news-releases/news-release-details/coopercompanies-announces-first-quarter-2026-results]. In the fiscal first quarter of 2025, the company's revenue increased 4% year-over-year to $964.7 million, with CooperVision revenue up 4% to $646.1 million and CooperSurgical revenue up 3% to $318.6 million [investor.coopercos.com/news-releases/news-release-details/coopercompanies-announces-first-quarter-2025-results].

The company regularly provides comprehensive financial information through its investor relations website, including quarterly materials, earnings releases, webcasts, transcripts, and SEC filings. Annual reports and proxy statements are also readily available, detailing the company's financial health and corporate governance [investor.coopercos.com/financial-information/quarterly-materials]. These documents include detailed discussions and analysis of financial condition and results of operations, quantitative and qualitative disclosures about market risk, and information on common equity and related stockholder matters [investor.coopercos.com/static-files/d141ee7e-35b1-47f5-8011-7d94ba240df4].

The Cooper Companies actively engages in a variety of events, primarily focusing on investor conferences and earnings calls to communicate with the financial community. These include regular Earnings Conference Calls, such as the Q2 2026 call held on June 4, 2026, which provides financial updates and guidance to stakeholders Q2 2026 CooperCompanies Earnings Conference Call - CooperCompanies.

The Cooper Companies also makes a point to participate in significant industry and investor conferences. For example, the company presented at the J.P. Morgan Healthcare Conference on January 14, 2026, with President and CEO Al White representing the company CooperCompanies to Present at the J.P. Morgan Healthcare Conference - CooperCompanies. Other notable participations include the 2024 Wells Fargo Healthcare Conference on September 4, 2024 CooperCompanies to Participate in Upcoming Investor Conferences - CooperCompanies and the William Blair Growth Stock Conference on June 5, 2025 CooperCompanies to Participate in the William Blair Growth Stock Conference - CooperCompanies.

Historically, The Cooper Companies has also engaged in events such as the Jefferies Healthcare Conference, with past participation in June 2022 Jefferies Healthcare Conference - CooperCompanies. These engagements are crucial for the company to disseminate information, discuss strategy, and connect with investors and analysts, highlighting its commitment to transparency and stakeholder communication Events & Presentations - CooperCompanies.